Cargando…

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?

While the contribution of autoreactive CD4(+) T cells to the pathogenesis of Multiple Sclerosis (MS) is widely accepted, the advent of B cell-depleting monoclonal antibody (mAb) therapies has shed new light on the complex cellular mechanisms underlying MS pathogenesis. Evidence supports the involvem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negron, Austin, Stüve, Olaf, Forsthuber, Thomas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753025/ https://www.ncbi.nlm.nih.gov/pubmed/33363512 http://dx.doi.org/10.3389/fneur.2020.607766

Ejemplares similares

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models
por: Zhan, Jiangshan, et al.
Publicado: (2021)

Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders
por: Chan, Koon Ho, et al.
Publicado: (2018)

Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003–2015
por: Schorner, Anja, et al.
Publicado: (2019)

Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis
por: Spain, Rebecca I., et al.
Publicado: (2023)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Ectopic lymphoid follicles: inducible centres for generating antigen‐specific immune responses within tissues
por: Jones, Gareth W., et al.
Publicado: (2015)

The role of the complement system in Multiple Sclerosis: A review
por: Saez-Calveras, Nil, et al.
Publicado: (2022)

Ectopic Lymphoid Follicle Formation and Human Seasonal Influenza Vaccination Responses Recapitulated in an Organ‐on‐a‐Chip
por: Goyal, Girija, et al.
Publicado: (2022)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

A Digital Patient Portal for Patients With Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2020)

Coagulation Pathways in Neurological Diseases: Multiple Sclerosis
por: Ziliotto, Nicole, et al.
Publicado: (2019)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022)

Editorial: Animal models of multiple sclerosis: can they advance future therapies?
por: DeSilva, Tara Maria, et al.
Publicado: (2023)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

The lymphoid follicle variant of dermatomyositis
por: Radke, Josefine, et al.
Publicado: (2014)

Comorbidity in Multiple Sclerosis
por: Magyari, Melinda, et al.
Publicado: (2020)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
por: Forsthuber, Thomas G., et al.
Publicado: (2018)

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
por: Manouchehri, Navid, et al.
Publicado: (2021)

B-cell–targeted therapies in relapsing forms of MS
por: Dubey, Divyanshu, et al.
Publicado: (2017)

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
por: Boziki, Marina, et al.
Publicado: (2021)

The Role of Antibodies in the Pathogenesis of Multiple Sclerosis
por: Yu, Xiaoli, et al.
Publicado: (2020)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

Restless leg syndrome in multiple sclerosis: a case–control study
por: Aljarallah, Salman, et al.
Publicado: (2023)

Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS)
por: Bäcker-Koduah, Priscilla, et al.
Publicado: (2020)

Study protocol: randomised controlled trial evaluating exercise therapy as a supplemental treatment strategy in early multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES)
por: Riemenschneider, Morten, et al.
Publicado: (2021)

Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial
por: Dörr, Jan, et al.
Publicado: (2018)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Editorial: Cognition in Multiple Sclerosis
por: Cortese, Rosa, et al.
Publicado: (2021)

Impact of Andropause on Multiple Sclerosis
por: Ysrraelit, Maria C., et al.
Publicado: (2021)

Therapeutic Advances in Multiple Sclerosis
por: Yang, Jennifer H., et al.
Publicado: (2022)

Editorial: Preventing multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2022)

Microglia in the context of multiple sclerosis
por: Zhang, Xue, et al.
Publicado: (2023)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Consensus on early detection of disease progression in patients with multiple sclerosis
por: Meca-Lallana, José E., et al.
Publicado: (2022)

Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_altab17jn8092ut313nsm707fo